• roche

    HOFFMANN-LA ROCHE

    PASEDENA

    This trial evaluates Prasinezumab’s effectiveness on treating early Parkinson’s Disease by slowing disease progression and motor symptoms. This is a monoclonal antibody targeting alpha-synuclein aggregates, aiming to improve quality of life for patients.

    Status: ACTIVE, NOT RECRUITING

    Apply
    Details
  • roche

    HOFFMANN-LA ROCHE

    PADOVA

    This trial evaluates Prasinezumab’s effectiveness on treating early Parkinson’s Disease by slowing disease progression and motor symptoms. This is a monoclonal antibody targeting alpha-synuclein aggregates, aiming to improve quality of life for patients. This is a 5-year extension study to PASEDENA.

    Status: ACTIVE, NOT RECRUITING

    Apply
    Details